HomeCompareEFF vs MRK

EFF vs MRK: Dividend Comparison 2026

EFF yields 44.51% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EFF wins by $237.8K in total portfolio value
10 years
EFF
EFF
● Live price
44.51%
Share price
$16.33
Annual div
$7.27
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$295.5K
Annual income
$54,522.85
Full EFF calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — EFF vs MRK

📍 EFF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEFFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EFF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EFF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EFF
Annual income on $10K today (after 15% tax)
$3,783.10/yr
After 10yr DRIP, annual income (after tax)
$46,344.42/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, EFF beats the other by $37,747.71/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EFF + MRK for your $10,000?

EFF: 50%MRK: 50%
100% MRK50/50100% EFF
Portfolio after 10yr
$176.6K
Annual income
$32,318.32/yr
Blended yield
18.30%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

EFF
No analyst data
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EFF buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEFFMRK
Forward yield44.51%2.81%
Annual dividend / share$7.27$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$295.5K$57.7K
Annual income after 10y$54,522.85$10,113.78
Total dividends collected$229.1K$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: EFF vs MRK ($10,000, DRIP)

YearEFF PortfolioEFF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$15,151$4,450.70$11,213$373.04+$3.9KEFF
2$22,513$6,301.99$12,667$512.06+$9.8KEFF
3$32,841$8,751.84$14,439$708.14+$18.4KEFF
4$47,071$11,931.47$16,640$988.16+$30.4KEFF
5$66,349$15,982.70$19,432$1,394.07+$46.9KEFF
6$92,048$21,054.48$23,057$1,992.90+$69.0KEFF
7$125,790$27,298.59$27,889$2,894.79+$97.9KEFF
8$169,460$34,864.87$34,518$4,286.29+$134.9KEFF
9$225,218$43,896.10$43,912$6,494.35+$181.3KEFF
10$295,507$54,522.85$57,714$10,113.78+$237.8KEFF

EFF vs MRK: Complete Analysis 2026

EFFStock

Eaton Vance Floating-Rate Income Plus Fund is a diversified closed-end management investment company. The Fund's investment objective is total return, with an emphasis on income. Its secondary objective is preservation of capital. The Fund invests primarily in below investment grade floating-rate loans. Under normal market conditions, the Fund invests approximately 80% of its total assets in senior loans of domestic and foreign borrowers that are denominated in the United States dollars and foreign currencies. Its portfolio includes investments in various locations, such as the United States, Luxembourg, Canada, the Netherlands, Cayman Islands and Australia. Its portfolio of investments includes aerospace and defense, automotive, chemicals and plastics, ecological services and equipment, electronics/electrical, utilities, food products, healthcare, insurance and financial intermediaries. Eaton Vance Management is an investment advisor to the Fund.

Full EFF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this EFF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EFF vs SCHDEFF vs JEPIEFF vs OEFF vs KOEFF vs MAINEFF vs JNJEFF vs ABBVEFF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.